When you suffer from chronic back pain, finding a treatment that helps you get relief from your discomfort can be trying. In some cases, if conservative treatments fail to reduce your pain or help you regain some of your normal function, surgery may be recommended. But surgery isn’t always the best choice for chronic back pain, due to the long recovery period and the possibility that it may not resolve your pain; or worse, lead to other back problems.
| Stem Cell, PRP, Acupuncture in Queens & Long Island, New York
Dealing with chronic pain can be frustrating as treatment after treatment offers temporary relief, but eventually, the debilitating pain creeps back in. As medical researchers cast about for longer-lasting solutions for chronic pain, many are focusing on stem cell therapy as a viable and sustainable solution that heals from within by tackling the source of your pain and addressing the problem through cell regeneration. Chronic pain may have met its match with stem cells.
Stem cell therapy is an innovative treatment for joint pain offered at Precision Pain Care and Rehabilitation. For many patients, stem cell therapy is a viable alternative to invasive surgery for pain relief. There is a lot of misleading information in the public sphere about what exactly stem cell therapy is, so make sure you get the facts before you decide whether or not this treatment is for you.
Neuropathic Pain - Treatment of neuropathic pain is a clinical challenge, as the pathogenesis is very complicated. The pathology of neuropathic pain involves the entire nervous systems, including the peripheral nerve, dorsal root ganglion, spinal cord, and brain. The main idea of applying stem cells to neuropathic pain is based on the ability of stem cells to release neurotrophic factors, along with providing a cellular source for replacing the injured neural cells, which make them ideal candidates for modulating and possibly reversing intractable neuropathic pain.
Although many countries including the USA, China, Italy, UK, France, Spain, Germany, Turkey, Iran, Brazil, and Jordon have proposed stem cell use for COVID‐19 patients, only a limited number of stem cell‐based studies are available currently to deduce solid limitations or potential of such therapy for COVID‐19. A study recently conducted in Beijing's YouAn Hospital, China, from January 23, 2020 to February 16, 2020 suggests a possible role of MSCs administration in COVID‐19 treatment (Leng et al., 2020).
Most COVID‐19 patients do not develop any major clinical symptoms during the early stages of infection. Common symptoms include mild or high temperature, cough, sore throat, muscle distress, and body pain. In a few patients, shortness of breath can lead to a sudden deterioration in the health of the patient during the later stages of the disease. In severe cases, immune system dysfunction is the major cause of death in patients as infection stimulates inflammatory cytokines that result in the respiratory system being overwhelmed by a storm of inflammatory cytokines such as interleukin 2 (IL‐2), IL‐6, granulocyte colony-stimulating factor, IP10, MCP1, MIP1A, and tumor necrosis factor.
Stem cells are unspecialized cells in the body that have the potential to make more stem cells as well as differentiate into specialized cells of the body if appropriate signals are given in vitro or in vivo. Embryonic stem cells (ESCs) can be isolated from the inner cell mass of 5–8 days old embryos and possess high regenerative potential. However, the clinical use of ESCs is restricted due to a number of religious, ethical, and legal controversies. Adult stem cells can be isolated from neonatal sources (such as cord blood, cord tissue, placenta, and menstrual blood) as well as from adult tissues (such as bone marrow, adipose tissue, dental pulp, and peripheral blood) are used for these purposes.
1,200 are already fully recovered from the effects of the virus. The Abu Dhabi Stem Cell Centre (ADSCC) has now treated more than 2000 patients suffering from COVID-19, with 1200 already fully recovered from the effects of the virus. ADSCC announced today that it had succeeded in ramping up the number of treatments from the 73 in the initial clinical trial. The large increase was as a result of a major effort by staff at the center to treat as many people as possible following the UAE Government’s decision to make it available free of charge to all moderate-to-high risk COVID-19 patients in the country.
Researchers announce the first patient has been dosed in a trial testing remestemcel-L, a stem cell therapy, in severe COVID-19 patients on ventilators. Testing of an experimental COVID-19 stem cell therapy has begun in the US. The therapy has been developed to treat hospitalized COVID-19 patients with moderate to severe acute respiratory distress syndrome (ARDS) who are on ventilators. A total of 300 are expected to be recruited into the randomized, placebo-controlled trial. The trial, in which patients will either receive the drug remestemcel-L or a placebo in addition to the recommended standard of care, is being conducted by the University of Maryland School of Medicine (UMSOM) researchers at the University of Maryland Medical Center (UMMC) and additional sites across the US. The first patient was treated at UMMC.
100 million adults in the United States - The majority of chronic pain in the United States is the result of a musculoskeletal injury stemming from trauma, disease, or illness. It is estimated that more than 100 million adults in the United States deal with some form of back pain throughout the year. And for many of these individuals, their back pain gradually goes from being acute to chronic.
Love this Post? Spread the World